home / stock / nnbxf / nnbxf quote
Last: | $15.90 |
---|---|
Change Percent: | 0.0% |
Open: | $15.9 |
Close: | $15.90 |
High: | $15.9 |
Low: | $15.9 |
Volume: | 4,000 |
Last Trade Date Time: | 05/21/2021 04:42:05 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$15.9 | $15.9 | $15.9 | $15.9 | $15.9 | 4,000 | 05-21-2021 |
$16.11 | $16.11 | $16.11 | $16.11 | $16.11 | 150 | 04-13-2021 |
$18 | $18 | $18 | $18 | $18 | 500 | 02-11-2021 |
$18.35 | $18.35 | $18.35 | $18.35 | $18.35 | 1,000 | 02-04-2021 |
$18.3 | $18.3 | $18.3 | $18.3 | $18.3 | 500 | 02-02-2021 |
$19.85 | $19.85 | $19.85 | $19.85 | $19.85 | 666 | 01-19-2021 |
$17.25 | $17.25 | $17.25 | $17.25 | $17.25 | 100 | 12-28-2020 |
$17.6 | $17.6 | $17.6 | $17.6 | $17.6 | 250 | 12-25-2020 |
$17.6 | $17.6 | $17.6 | $17.6 | $17.6 | 250 | 12-24-2020 |
$16.25 | $16.25 | $16.25 | $16.25 | $16.25 | 426 | 12-11-2020 |
$14.95 | $14.8183 | $14.95 | $14.95 | $14.8183 | 214 | 12-10-2020 |
$15.35 | $15.35 | $15.35 | $15.35 | $15.35 | 250 | 12-09-2020 |
$15.25 | $15.25 | $15.25 | $15.25 | $15.25 | 100 | 11-30-2020 |
$12.9014 | $12.901419 | $12.9014 | $12.9014 | $12.9014 | 4,235 | 11-20-2020 |
$7.32 | $7.32 | $7.32 | $7.32 | $7.32 | 1,500 | 04-20-2020 |
News, Short Squeeze, Breakout and More Instantly...
Nanobiotix SA Company Name:
NNBXF Stock Symbol:
OTCMKTS Market:
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial effi...
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy Confirmation of injection feasibility and favorable safety profile in completed ...